Limits...
HOXB7-S3 inhibits the proliferation and invasion of MCF-7 human breast cancer cells.

Ma R, Zhang D, Hu PC, Li Q, Lin CY - Mol Med Rep (2015)

Bottom Line: Subsequently, small interfering RNAs designed to interfere with the expression of HOXB7 were used to knockdown the expression of HOXB7 in the MCF‑7 cell line, the effects of which on cell proliferation, the apoptotic rate and invasion capacity were measured using a Cell Counting kit‑8 assay, flow cytometry and transwell chambers, respectively.Furthermore, HOXB7‑S3 effectively inhibited the proliferation and invasion of MCF‑7 breast cancer cells.In conclusion, these results demonstrated that HOXB7 may be a potential therapeutic target in human breast cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei Cancer Clinical Study Center, Key Laboratory of Tumor Biological Behavior of Hubei, Wuhan, Hubei 430071, P.R. China.

ABSTRACT
Homeobox B7 (HOXB7) has been found to be overexpressed in numerous types of human cancer. However, the role of HOXB7 in breast cancer remains to be elucidated. The aim of the present study was to investigate the effects of HOXB7 on the proliferation and invasion of breast cancer cells. Initially, reverse transcription quantitative polymerase chain reaction and western blotting were respectively employed to detect the mRNA and protein expression levels of the HOXB7 gene in the MDA‑MB‑231 and MCF‑7 human breast cancer cell lines. Subsequently, small interfering RNAs designed to interfere with the expression of HOXB7 were used to knockdown the expression of HOXB7 in the MCF‑7 cell line, the effects of which on cell proliferation, the apoptotic rate and invasion capacity were measured using a Cell Counting kit‑8 assay, flow cytometry and transwell chambers, respectively. The results demonstrated that HOXB7 mRNA and protein were all overexpressed in MDA‑MB‑231 and MCF‑7 breast cancer cell lines. Furthermore, HOXB7‑S3 effectively inhibited the proliferation and invasion of MCF‑7 breast cancer cells. In conclusion, these results demonstrated that HOXB7 may be a potential therapeutic target in human breast cancer.

Show MeSH

Related in: MedlinePlus

CCK-8 test of cell proliferation. Con-B group, blank control group; Sn group, negative control siRNA; S3 group, S3 transfection group. The CCK-8 test demonstrated that the cell viability of the S3 group was significantly decreased compared with the other two groups between 48 and 72 h and the difference was statistically significant (***P<0.001). Data are presented as the average of three independent experiments each containing five replicates. CCK-8, cell counting kit-8; siRNA, small interfering RNA.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4581815&req=5

f6-mmr-12-04-4901: CCK-8 test of cell proliferation. Con-B group, blank control group; Sn group, negative control siRNA; S3 group, S3 transfection group. The CCK-8 test demonstrated that the cell viability of the S3 group was significantly decreased compared with the other two groups between 48 and 72 h and the difference was statistically significant (***P<0.001). Data are presented as the average of three independent experiments each containing five replicates. CCK-8, cell counting kit-8; siRNA, small interfering RNA.

Mentions: To determine the effect of HOXB7-S3 on cell proliferation in MCF-7 breast cancer cells, a CCK-8 assay was used. As shown in Fig. 6, the cell viability of the three groups demonstrated no significant difference following transfection with HOXB7-S3 or HOXB7-Sn for 24 h. Between 48 and 72 h, the cell viability of the S3 group was significantly decreased compared with that of the Con-B groups. In particular, the cell viability of the S3 group (74.43±2.55%) at 48 h post-transfection was significantly decreased compared with that of the Con-B group (111.97±3.66%) and Sn group (100±1.58%). The difference was statistically significant (***P<0.001). The cell viability of the S3 group at 96 h post-transfection demonstrated a partially decreased cell survival, however, this decease was not so pronounced. This result demonstrated that HOXB7-S3 could effectively and significantly inhibit the proliferation of human breast cancer MCF-7 cells.


HOXB7-S3 inhibits the proliferation and invasion of MCF-7 human breast cancer cells.

Ma R, Zhang D, Hu PC, Li Q, Lin CY - Mol Med Rep (2015)

CCK-8 test of cell proliferation. Con-B group, blank control group; Sn group, negative control siRNA; S3 group, S3 transfection group. The CCK-8 test demonstrated that the cell viability of the S3 group was significantly decreased compared with the other two groups between 48 and 72 h and the difference was statistically significant (***P<0.001). Data are presented as the average of three independent experiments each containing five replicates. CCK-8, cell counting kit-8; siRNA, small interfering RNA.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4581815&req=5

f6-mmr-12-04-4901: CCK-8 test of cell proliferation. Con-B group, blank control group; Sn group, negative control siRNA; S3 group, S3 transfection group. The CCK-8 test demonstrated that the cell viability of the S3 group was significantly decreased compared with the other two groups between 48 and 72 h and the difference was statistically significant (***P<0.001). Data are presented as the average of three independent experiments each containing five replicates. CCK-8, cell counting kit-8; siRNA, small interfering RNA.
Mentions: To determine the effect of HOXB7-S3 on cell proliferation in MCF-7 breast cancer cells, a CCK-8 assay was used. As shown in Fig. 6, the cell viability of the three groups demonstrated no significant difference following transfection with HOXB7-S3 or HOXB7-Sn for 24 h. Between 48 and 72 h, the cell viability of the S3 group was significantly decreased compared with that of the Con-B groups. In particular, the cell viability of the S3 group (74.43±2.55%) at 48 h post-transfection was significantly decreased compared with that of the Con-B group (111.97±3.66%) and Sn group (100±1.58%). The difference was statistically significant (***P<0.001). The cell viability of the S3 group at 96 h post-transfection demonstrated a partially decreased cell survival, however, this decease was not so pronounced. This result demonstrated that HOXB7-S3 could effectively and significantly inhibit the proliferation of human breast cancer MCF-7 cells.

Bottom Line: Subsequently, small interfering RNAs designed to interfere with the expression of HOXB7 were used to knockdown the expression of HOXB7 in the MCF‑7 cell line, the effects of which on cell proliferation, the apoptotic rate and invasion capacity were measured using a Cell Counting kit‑8 assay, flow cytometry and transwell chambers, respectively.Furthermore, HOXB7‑S3 effectively inhibited the proliferation and invasion of MCF‑7 breast cancer cells.In conclusion, these results demonstrated that HOXB7 may be a potential therapeutic target in human breast cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei Cancer Clinical Study Center, Key Laboratory of Tumor Biological Behavior of Hubei, Wuhan, Hubei 430071, P.R. China.

ABSTRACT
Homeobox B7 (HOXB7) has been found to be overexpressed in numerous types of human cancer. However, the role of HOXB7 in breast cancer remains to be elucidated. The aim of the present study was to investigate the effects of HOXB7 on the proliferation and invasion of breast cancer cells. Initially, reverse transcription quantitative polymerase chain reaction and western blotting were respectively employed to detect the mRNA and protein expression levels of the HOXB7 gene in the MDA‑MB‑231 and MCF‑7 human breast cancer cell lines. Subsequently, small interfering RNAs designed to interfere with the expression of HOXB7 were used to knockdown the expression of HOXB7 in the MCF‑7 cell line, the effects of which on cell proliferation, the apoptotic rate and invasion capacity were measured using a Cell Counting kit‑8 assay, flow cytometry and transwell chambers, respectively. The results demonstrated that HOXB7 mRNA and protein were all overexpressed in MDA‑MB‑231 and MCF‑7 breast cancer cell lines. Furthermore, HOXB7‑S3 effectively inhibited the proliferation and invasion of MCF‑7 breast cancer cells. In conclusion, these results demonstrated that HOXB7 may be a potential therapeutic target in human breast cancer.

Show MeSH
Related in: MedlinePlus